 "Lupin Pharma")
Drug major Lupin has received final approval from the US health regulator to market Voriconazole tablets, used for the treatment of fungal infections, in the American market.
"Its US subsidiary, Gavis Pharmaceuticals LLC (collectively Lupin), has received final approval for its Voriconazole Tablets, 50 mg and 200 mg, and Voriconazole Oral Suspension, 40 mg/mL, from the United States Food and Drug Administration (USFDA) to market a generic equivalent of PF Prism CV's Vfend Tablets," the company said in a BSE filing.
It further said, the company shall commence promoting the products in the US shortly.
According to IMS MAT March 2016 sales data, Vfend tablets, 50 mg and 200 mg, had sales of $92.8 million, while Vfend Oral Suspension, 40 mg/mL, had US sales of $15.9 million.
Lupin shares were trading 0.51% down at Rs 1,441.70 on BSE in the afternoon session.
